Search

Your search keyword '"Jarai, Rudolf"' showing total 146 results
Start Over Author "Jarai, Rudolf"
146 results on '"Jarai, Rudolf"'

2. Usefulness of Elevated Levels of Growth Differentiation Factor-15 to Classify Patients With Acute Coronary Syndrome Having Percutaneous Coronary Intervention Who Would Benefit from High-Dose Statin Therapy

Author

Tentzeris, Ioannis, Farhan, Serdar, Freynhofer, Matthias Karl, Rohla, Miklos, Jarai, Rudolf, Vogel, Birgit, Baumgartner-Parzer, Sabina, Nürnberg, Michael, Geppert, Alexander, Wessely, Emil, Wojta, Johann, Huber, Kurt, and Kautzky-Willer, Alexandra

Published
2017
Full Text
View/download PDF

9. Plasma N-terminal fragment of the prohormone B-type natriuretic peptide concentrations in relation to time to treatment and Thrombolysis in Myocardial Infarction (TIMI) flow: A substudy of the Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT IV-PCI) trial

Author

Jarai, Rudolf, Huber, Kurt, Bogaerts, Kris, Droogne, Walter, Ezekowitz, Justin, Granger, Christopher B., Sinnaeve, Peter R., Ross, Allan M., Zeymer, Uwe, Armstrong, Paul W., and Van de Werf, Frans J.

Published
2010
Full Text
View/download PDF

23. Soluble ST2 and Interleukin-33 Levels in Coronary Artery Disease: Relation to Disease Activity and Adverse Outcome

Author

Demyanets, Svitlana, primary, Speidl, Walter S., additional, Tentzeris, Ioannis, additional, Jarai, Rudolf, additional, Katsaros, Katharina M., additional, Farhan, Serdar, additional, Krychtiuk, Konstantin A., additional, Wonnerth, Anna, additional, Weiss, Thomas W., additional, Huber, Kurt, additional, and Wojta, Johann, additional

Published
2014
Full Text
View/download PDF

27. B-type Natriuretic Peptide and Risk of Contrast-Induced Acute Kidney Injury in Acute ST-Segment–Elevation Myocardial Infarction

Author

Jarai, Rudolf, primary, Dangas, George, additional, Huber, Kurt, additional, Xu, Ke, additional, Brodie, Bruce R., additional, Witzenbichler, Bernhard, additional, Metzger, D. Christopher, additional, Radke, Peter W., additional, Yu, Jennifer, additional, Claessen, Bimmer E., additional, Genereux, Philippe, additional, Mehran, Roxana, additional, and Stone, Gregg W., additional

Published
2012
Full Text
View/download PDF

32. Activated protein C levels and outcome in patients with cardiogenic shock complicating acute myocardial infarction

Author

Fellner, Barbara, Rohla, Miklos, Jarai, Rudolf, Smetana, Peter, Freynhofer, Matthias K, Egger, Florian, Zorn, Gerlinde, Weiss, Thomas W, Huber, Kurt, and Geppert, Alexander

Abstract

Introduction: In patients with severe sepsis, low levels of activated protein C are associated with high morbidity and mortality. In an observational study we investigated whether patients with cardiogenic shock have decreased circulatory levels of activated protein C, and if these are associated with increased mortality.Methods: We measured serum activated protein C and interleukin-6 levels in 43 patients with cardiogenic shock following acute myocardial infarction and in 15 control patients with uncomplicated myocardial infarction at days 0–5 and 7 after the onset of shock/myocardial infarction.Results: Activated protein C levels were significantly lower in patients with cardiogenic shock compared to controls. In cardiogenic shock patients, there was no difference in activated protein C levels at baseline, whereas activated protein C levels significantly declined in 28-day non-survivors at day 2, compared with 28-day survivors. Lower levels of activated protein C were associated with a higher degree of vasopressor need, whereas there was no significant association with multiple organ failure in the first days. Regarding the inflammatory response, a strong inverse correlation was observed between interleukin-6 and activated protein C levels.Conclusion: Patients with cardiogenic shock who did not survive up to 28 days showed a decline in activated protein C levels during the course of the disease, which was inversely correlated with interleukin-6. This study underlines sustained inflammatory mechanisms in the development and persistence of cardiogenic shock, highlighting a potential effect of anti-inflammatory interventions early during cardiogenic shock.

Published
2017
Full Text
View/download PDF

38. Prediction of cardiogenic shock using plasma B-type natriuretic peptide and the N-terminal fragment of its pro-hormone concentrations in ST elevation myocardial infarction: An analysis from the ASSENT-4 Percutaneous Coronary Intervention Trial

Author

Jarai, Rudolf, primary, Huber, Kurt, additional, Bogaerts, Kris, additional, Sinnaeve, Peter R., additional, Ezekowitz, Justin, additional, Ross, Allan M., additional, Zeymer, Uwe, additional, Armstrong, Paul W., additional, and Van de Werf, Frans J., additional

Published
2010
Full Text
View/download PDF

44. Risk assessment in patients with unstable angina/non-ST-elevation myocardial infarction and normal N-terminal pro-brain natriuretic peptide levels by N-terminal pro-atrial natriuretic peptide

Author

Jarai, Rudolf, primary, Iordanova, Nelly, additional, Jarai, Robert, additional, Raffetseder, Annamaria, additional, Woloszczuk, Wolfgang, additional, Gyöngyösi, Mariann, additional, Geyer, Georg, additional, Wojta, Johann, additional, and Huber, Kurt, additional

Published
2004
Full Text
View/download PDF

46. Sex-related differences in baseline characteristics, management and outcome in patients with acute coronary syndrome without ST-segment elevation

Author

Vogel, Birgit, Farhan, Serdar, Hahne, Sarah, Kozanli, Ilyas, Kalla, K, Freynhofer, Matthias K, Jarai, Rudolf, Kautzky-Willer, Alexandra, and Huber, Kurt

Abstract

Aim: To detect sex-related differences in baseline characteristics, management and outcome in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS).Methods: Data from 812 consecutive patients admitted to our cardiology department for NSTE-ACS between 2001 and 2004 were obtained. Early invasive therapy was defined as revascularization during first hospital stay. A seven-year follow-up for the clinical endpoint of all-cause mortality could be obtained in 342 women and 440 men, respectively.Results: Compared with men, women were significantly older and more likely to suffer from renal insufficiency. The proportion treated with clopidogrel at admission was 43.6% for women and 52.7% for men, respectively (p=0.011). Significantly fewer women underwent an early invasive therapy compared with men (27.5% vs. 35.2%; p=0.021). Age and renal insufficiency were the strongest predictors for a conservative approach in both female and male patients. After adjustment for baseline characteristics there was no significant difference in treatment between women and men (odds ratio 0.89; 95% confidence interval 0.59–1.35; p=0.588). While in-hospital mortality was similar between the sexes, long-term mortality was significantly higher in women compared with men (8.2% vs. 7.0%; p=0.549 for in-hospital mortality and 54.8% vs. 39.3%; p<0.001 for seven-year mortality). However, after adjustment for baseline characteristics and treatment there was no significant difference in long-term mortality between women and men (hazard ratio 1.14; 95% confidence interval 0.89–1.47; p=0.307).Conclusion: In these patients with NSTE-ACS women were less likely to undergo an early invasive therapy compared with men due to their higher age and the higher rate of renal insufficiency. After adjustment for age, comorbidities and treatment female sex was not associated with worse long-term outcome.

Published
2016
Full Text
View/download PDF

47. Contrast induced acute kidney injury in acute coronary syndrome patients: A single centre experience

Author

Farhan, Serdar, Vogel, Birgit, Tentzeris, Ioannis, Jarai, Rudolf, Freynhofer, Matthias Karl, Smetana, Peter, Egger, Florian, Kautzky-Willer, Alexandra, and Huber, Kurt

Abstract

Background: The aim of the study was to investigate predictors of contrast induced acute kidney injury, in-hospital and long-term mortality in patients with acute coronary syndrome treated by percutaneous coronary intervention.Methods: We investigated 536 consecutive patients with acute coronary syndrome who underwent percutaneous coronary intervention. Contrast induced acute kidney injury was classified according to risk, injury, failure, loss of kidney function and end-stage kidney disease/acute kidney injury network (RIFLE/AKIN) criteria into those with normal kidney function, risk, RIFLE stage I and those with stage ?II. We investigated in-hospital, all-cause mortality during index hospitalization and long-term all-cause mortality during the follow-up period of 94 months (interquartile 81.6–108.9 months) in adjustment with parameters of the Global Risk of Acute Coronary Events score.Results: Patients with contrast induced acute kidney injury had worse baseline clinical characteristics and displayed more co-morbidities than patients with normal kidney function. In multivariate logistic regression analysis intra-aortic balloon pump use, congestive heart failure, age >75 years and admission serum creatinine >1.5mg/dl were independent predictors of contrast induced acute kidney injury development. contrast induced acute kidney injury RIFLE stage ?II was an independent predictor of in-hospital mortality (odds ratio 33.16, confidence interval 1.426–770.79, p=0.029) and long-term mortality (hazard ratio 4.713, confidence interval 1.53–14.51, p=0.007) even after adjustment for confounders (variables of Global Risk of Acute Coronary Events score).Conclusion: Contrast induced acute kidney injury is a common complication of acute coronary syndrome patients treated by percutaneous coronary intervention. Advanced deterioration in renal function after percutaneous coronary intervention is an independent predictor for in-hospital and long-term mortality.

Published
2016
Full Text
View/download PDF

48. Variability of on-treatment platelet reactivity in patients on clopidogrel.

Author

Freynhofer, Matthias K., Bruno, Veronika, Brozovic, Ivan, Jarai, Rudolf, Vogel, Birgit, Farhan, Serdar, Hübl, Wolfgang, Willheim, Martin, Wojta, Johann, and Huber, Kurt

Subjects
CLOPIDOGREL, PLATELET aggregation inhibitors, ACUTE coronary syndrome, BODY mass index, MYOCARDIAL infarction, QUALITY of life, PATIENTS
Abstract

Response to clopidogrel therapy is subject to inter-individual variability. However, data with regard to on-treatment platelet reactivity over time in patients undergoing coronary stenting are scarce. For this prospective observational study, 102 consecutive patients on dual antiplatelet therapy undergoing coronary stenting due to stable coronary artery disease (CAD; n = 29), non ST-elevation acute coronary syndrome (NSTE-ACS; n = 45) and ST-elevation myocardial infarction (STEMI; n = 28) were enrolled. Vasodilator-stimulated phosphoprotein-phosphorylation assay was performed at baseline, as well as 1, 3 and 6 months thereafter. Platelet reactivity index (PRI) measured after 1, 3 and 6 months was lower compared to baseline values ( p < 0.001). Variables responsible for reduced response to clopidogrel at baseline (reticulated platelet fraction, simvastatin therapy) and during steady-state phase (body mass index, blood glucose concentrations, cholesterol/HDL-ratio and quality of life score) were different. High on-treatment platelet reactivity (HTPR)-phenotype (cut-off = 50% PRI) within the first month changed in 31% of stable CAD, 33% of NSTE-ACS and 39% of STEMI patients, respectively. HTPR-phenotype in the steady-state phase (month 1 to 6) changed in 45% of stable CAD, 33% of NSTE-ACS and 25% of STEMI patients. Response to clopidogrel and accordingly platelet function might vary over time, especially when a cut-off based approach, is used. There was a significant reduction of on-treatment platelet reactivity within the first month after percutaneous coronary intervention with stenting which was maintained for up to 6 months. Variables associated with reduced response to clopidogrel at baseline and during steady-state phase were different, as the latter mainly reflected an unfavorable metabolic profile, comprising elevated BMI, blood glucose levels as well as cholesterol/HDL-ratio. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results